Teva Pharmaceutical

Sanofi shows how $500M IBD bet compares to Merck, Roche rivals

Sanofi shared a deeper dive into phase 2 data, providing a clearer look at how the Teva-partnered prospect compares to Merck and Roche’s rival assets.

Nick Paul Taylor Feb 24, 2025 8:11am

Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC

Dec 17, 2024 10:30am

Teva brings biotech ethos to drug development, exec says

Oct 15, 2024 4:33pm

Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders

Feb 9, 2024 9:30am

Gene editor Metagenomi adds C-suite execs—Chutes & Ladders

Nov 10, 2023 9:30am

Sanofi pays Teva $500M to join red-hot bowel disease race

Oct 4, 2023 6:00am